<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518959</url>
  </required_header>
  <id_info>
    <org_study_id>D-HEM</org_study_id>
    <nct_id>NCT01518959</nct_id>
  </id_info>
  <brief_title>The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases</brief_title>
  <acronym>D-HEM</acronym>
  <official_title>Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data have shown that the inadequate vitamin D status plays a role in the manifestation
      of the haematologic tumors and serum vitamin D level has a prognostic role also as it
      determines the tumor mortality. But data have not proved a causal relationship between the
      inadequate vitamin D status and the unfavourable outcomes so far. It is also still unknown,
      whether the normalization of vitamin D status in patient with vitamin D inadequacy is able to
      improve the prognosis and survival.

      In this study the investigators examine the role of the adequate vitamin D substitution in
      the improvement of the outcomes of haematologic disorders.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment needed</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lymphocyte count</measure>
    <time_frame>monthly, up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalcipherol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with 180 000 IU cholecalcipherol monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>180.000 IU monthly</description>
    <arm_group_label>Cholecalcipherol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oleum neutralicum</intervention_name>
    <description>Placebo comparator, 9 ml monthly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years old male or female

          -  chronic lymphoid leukaemia, any Rai stage

          -  25-OH-Vitamin-D3 level between 10 and 30 ng/mL

        Exclusion Criteria:

          -  serum calcium &gt; 2,60 mmol/l

          -  24 hour calcium urine excretion &gt; 0,1 mmol/kg/day

          -  serum phosphate &gt; 1,45 mmol/l

          -  eGFR &lt; 30 ml/min/1,73m2

          -  nephrolithiasis

          -  receiving parenteral vitamin-D3 in past 6 months

          -  activated vitamin-D3 treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Istvan Takacs, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Istvan Takacs, M.D., Ph.D.</last_name>
    <phone>+36-1-210-0278</phone>
    <phone_ext>51500</phone_ext>
    <email>takist@bel1.sote.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Semmelweis University - 1st Departement of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Takacs, MD, PhD</last_name>
      <phone>+36-1-210-0278</phone>
      <phone_ext>51500</phone_ext>
      <email>takist@bel1.sote.hu</email>
    </contact>
    <investigator>
      <last_name>Istvan Takacs, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Istvan Takacs</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

